
Paolo Tarantino/X
May 31, 2025, 11:04
Paolo Tarantino: Interesting Results From a 1L Trial of CDK4/6 Inhibitors in Triple-Positive MBC at ASCO 2025
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment.“
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 31, 2025, 10:23
May 31, 2025, 10:21
May 31, 2025, 10:07
May 31, 2025, 10:00
May 31, 2025, 09:56